Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Labcorp Holdings Inc. (LH)

NYQ · Diagnostics & Research

$314.23+13.06 (+4.34%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$25.77B
P/E (TTM)
27.86
EPS
$11.28
Div Yield
0.92%
52W Range
$244.52–$315.77
Beta
0.86

Company overview

Next earnings: 2026-07-30(2d)

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Peers in Diagnostics & Research

All in industry →

Recent press releases

April 2026

3 months agoARSHealthcare

LabCorp Annual Report Highlights Dual-Engine Growth Strategy

LHLABCORP HOLDINGS INC.

# 🧾 What This Document Is This is an **Annual Report to Shareholders (ARS)**. It's a company's yearly "report card" and storybook, meant to give investors a comprehensive look at the business, its performance, and its future plans. It's typically more narrative and visually friendly than a dense 10

Read summaryView on SEC EDGAR
3 months agoDEF 14AHealthcare

LABCORP HOLDINGS INC. — DEF 14A Filing

LHLABCORP HOLDINGS INC.

# 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)** for Labcorp Holdings Inc. Think of it as a detailed "shareholder guidebook" sent ahead of the annual meeting. It explains what the company did in 2025, who runs it, how they are paid, and what shareholders need to vote on.

Read summaryView on SEC EDGAR

March 2026

4 months ago8-KHealthcare

LABCORP HOLDINGS INC. — 8-K Filing

LHLABCORP HOLDINGS INC.

# 🔥 What This Document Is This is a Form 8-K, which is a current report companies file with the SEC to announce major, specific events that shareholders should know about right away. 👉 In this case, Labcorp is using it to tell the public and the financial markets exactly when it will release its

Read summaryView on SEC EDGAR

SEC filings

All filings →
3 recent filings shown in the timeline above. View all SEC filings →

Labcorp Holdings Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
6,540,781 sh-19.5%
5,356,825 sh+103.1%
1,913,695 sh● NEW
573,923 sh-67.6%
9,850,631 sh+0.4%
686,893 sh-54.4%
967,679 sh-36.4%
1,260,116 sh-23.3%

People at Labcorp Holdings Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$5.8M
NI
06/25
$2.93B
NI $237.9M
09/25
$3.56B
NI $261.1M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $3.12
Prior: $2.84
Revenue sparkline